Drug Trial Radar · NCT04543071
Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
118
Planned (sponsor's estimate)
Start
Nov 9, 2020
Primary completion
Jun 2028
Study completion Aug 2028
Sponsor
- Lead sponsor
- Columbia UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Regeneron Pharmaceuticals; BioLine Rx
- First posted
- Sep 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if combination treatment with cemiplimab, motixafortide, gemcitabine, and nab-paclitaxel is effective in decreasing the size of the tumor(s), if it will prolong life in patients, and if it's safe. The treatment consists of standard chemotherapy (gemcitabine and nab-paclitaxel) which is FDA approved and is standard treatment for patients with pancreatic adenocarcinoma. Participants will receive immunotherapy (cemiplimab) which activates the body's immune system to attack cancer cells. Cemiplimab is FDA approved for treatment of skin cancer but not for pancreas cancer. Participants will also receive Motixafortide, a new medication which has shown in the laboratory to help immunotherapy work better. Motixafortide has been tested together with immunotherapy (Pembrolizumab), and chemotherapy (5-Fluorouracil and liposomal Irinotecan) and was deemed safe to test additional patients. Motixafortide has not been tested with the specific immunotherapy (Cemiplimab) and chemotherapy (gemcitabine and nab-paclitaxel) which participants will receive and is being tested in this clinical trial.
Conditions
- Pancreatic Cancer
- Adenocarcinoma of the Pancreas
- Adenocarcinoma
Interventions
MotixafortideDrug
1.25 mg/kg subcutaneous (SC) monotherapy daily for 5 days during priming, followed by twice weekly
CemiplimabDrug
350 mg intravenous (IV) once every 21 days
GemcitabineDrug
1000 mg/m2 IV on days days 1, 8, 14 (every 28 days)
Nab paclitaxelDrug
125 mg/m2 IV on days 1, 8, 14 (every 28 days)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (Complete Response (CR) + Partial Response (PR))Time frame: 16 weeks
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Columbia University Irving Medical Center
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Brown University
Providence, Rhode Island
Medical College of Wisconsin, Wisconsin Diagnostic Labratories
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.